After rejection and appeal, Omeros saddles up for 2nd charge at transplant drug approval

The biotech is preparing to resubmit its application for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy, the company revealed in its fourth-quarter earnings report. In fact, Omeros has already requested a meeting with the agency, expected to take place in the second quarter, to confirm additional information that will need to be provided.